07:45 AM EST, 11/05/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

Bio-Techne ( TECH ) reported Q1 FY 26 (Jun.) adjusted EPS of $0.42 (flat Y/Y), in line with consensus, while revenue declined 1% Y/Y to $286.6M, below consensus. The company navigated a challenging operating environment marked by persistent biotech funding headwinds, though signs of U.S. academic market stabilization emerged. The recently completed Exosome Diagnostics divestiture represents a strategic pivot toward non-CLIA based product lines, which should enhance focus on higher-growth opportunities, in our view. Management's cost control initiatives drove adjusted operating margin expansion to 29.9%, up 90 basis points Y/Y. The core Protein Sciences segment (71% of revenue) declined 1% Y/Y to $202.2M, with organic revenue down 3% Y/Y, while Diagnostics segment revenue fell 4% Y/Y to $79.5M, though organic growth was positive at 3% Y/Y. We think the divestiture should improve the Diagnostics segment's profitability profile while maintaining access to proprietary exosome-based technology for ongoing kit development.